Y-Mabs Therapeutics (YMAB) Stock Statistics & Valuation Metrics

Y-Mabs Therapeutics has a market cap or net worth of $387.14M. The enterprise value is $145.22M.

Y-Mabs Therapeutics has 45,438,420 shares outstanding. The number of shares has decreased by -2.65% in one year.

Y-Mabs Therapeutics’s return on equity (ROE) is -0.32 and return on invested capital (ROIC) is -32.06%.

The current PE Ratio of Y-Mabs Therapeutics is ―. Y-Mabs Therapeutics’s PEG ratio is ―.

In the last 12 months, Y-Mabs Therapeutics had revenue of 87.69M and earned -29.67M in profits. Earnings per share was -0.67.

In the last 12 months, operating cash flow was -17.80M and capital expenditures -127.00K, giving a free cash flow of -17.92M billion.

Y-Mabs Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Y-Mabs Therapeutics upcoming earnings date is Nov 6, 2025, TBA (Confirmed).

Y-Mabs Therapeutics as a current ratio of 4.16, with Debt / Equity ratio of 3.57%

In the past 12 months, Y-Mabs Therapeutics has paid -146.00K in taxes.

Y-Mabs Therapeutics EV to EBITDA ratio is -9.15, with an EV/FCF ratio of -17.86.

Y-Mabs Therapeutics has $62.29M in cash and marketable securities with $3.12M in debt, giving a net cash position of -$59.17M billion.

Gross margin is 81.55%, with operating margin of -35.58%, and net profit margin of -33.83%.

The average price target for Y-Mabs Therapeutics is $8.68, which is 11.43% higher than the current price. The consensus rating is Hold